Q32 Bio Total Assets Growth & History (QTTB)
Q32 Bio's total assets was $61.8M for fiscal 2025.
View full Q32 Bio company overviewQ32 Bio annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $61.8M | −$30.6M | −33.09% |
| 2024 | 2024-12-31 | $92.3M | $45.3M | +96.21% |
| 2023 | 2023-12-31 | $47.1M | −$181.4M | −79.40% |
| 2022 | 2022-12-31 | $228.5M | $16.7M | +7.91% |
| 2021 | 2021-12-31 | $211.7M | −$52.0M | −19.72% |
| 2020 | 2020-12-31 | $263.7M | −$46.8M | −15.08% |
| 2019 | 2019-12-31 | $310.6M | $51.5M | +19.87% |
| 2018 | 2018-12-31 | $259.1M | $121.6M | +88.39% |
| 2017 | 2017-12-31 | $137.5M | — | — |
Q32 Bio quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $115.9M | $49.8M | +75.25% |
| Q1 2026 | 2026-03-31 | $63.7M | −$15.4M | −19.47% |
| Q4 2025 | 2025-12-31 | $61.8M | −$30.6M | −33.09% |
| Q3 2025 | 2025-09-30 | $57.8M | −$46.8M | −44.73% |
| Q2 2025 | 2025-06-30 | $66.1M | −$58.1M | −46.77% |
| Q1 2025 | 2025-03-31 | $79.1M | −$73.3M | −48.09% |
| Q4 2024 | 2024-12-31 | $92.3M | $45.3M | +96.21% |
| Q3 2024 | 2024-09-30 | $104.5M | −$35.5M | −25.36% |
| Q2 2024 | 2024-06-30 | $124.2M | −$45.1M | −26.65% |
| Q1 2024 | 2024-03-31 | $152.3M | −$45.5M | −23.02% |
| Q4 2023 | 2023-12-31 | $47.1M | −$181.4M | −79.40% |
| Q3 2023 | 2023-09-30 | $140.1M | −$122.6M | −46.67% |
| Q2 2023 | 2023-06-30 | $169.3M | −$115.3M | −40.50% |
| Q1 2023 | 2023-03-31 | $197.9M | −$113.1M | −36.36% |
| Q4 2022 | 2022-12-31 | $228.5M | $16.7M | +7.91% |
| Q3 2022 | 2022-09-30 | $262.7M | $31.8M | +13.79% |
| Q2 2022 | 2022-06-30 | $284.6M | $25.7M | +9.92% |
| Q1 2022 | 2022-03-31 | $311.0M | $76.3M | +32.49% |
| Q4 2021 | 2021-12-31 | $211.7M | −$52.0M | −19.72% |
| Q3 2021 | 2021-09-30 | $230.8M | $2.5M | +1.07% |
| Q2 2021 | 2021-06-30 | $258.9M | $680,000 | +0.26% |
| Q1 2021 | 2021-03-31 | $234.7M | −$54.1M | −18.73% |
| Q4 2020 | 2020-12-31 | $263.7M | −$46.8M | −15.08% |
| Q3 2020 | 2020-09-30 | $228.4M | −$88.4M | −27.91% |
| Q2 2020 | 2020-06-30 | $258.2M | −$82.9M | −24.31% |
| Q1 2020 | 2020-03-31 | $288.8M | $55.8M | +23.93% |
| Q4 2019 | 2019-12-31 | $310.6M | $51.5M | +19.87% |
| Q3 2019 | 2019-09-30 | $316.8M | $48.4M | +18.02% |
| Q2 2019 | 2019-06-30 | $341.2M | $70.8M | +26.21% |
| Q1 2019 | 2019-03-31 | $233.0M | $103.9M | +80.53% |
| Q4 2018 | 2018-12-31 | $259.1M | $121.6M | +88.39% |
| Q3 2018 | 2018-09-30 | $268.4M | — | — |
| Q2 2018 | 2018-06-30 | $270.3M | — | — |
| Q1 2018 | 2018-03-31 | $129.1M | — | — |
| Q4 2017 | 2017-12-31 | $137.5M | — | — |
Q32 Bio total assets trends
Over the last five fiscal years, Q32 Bio's total assets decreased from $263.7M to $61.8M, a change of −$202.0M. The latest reported quarter, Q2 2026, shows $115.9M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Q32 Bio source filings ↗